MX2020009530A - Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. - Google Patents
Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.Info
- Publication number
- MX2020009530A MX2020009530A MX2020009530A MX2020009530A MX2020009530A MX 2020009530 A MX2020009530 A MX 2020009530A MX 2020009530 A MX2020009530 A MX 2020009530A MX 2020009530 A MX2020009530 A MX 2020009530A MX 2020009530 A MX2020009530 A MX 2020009530A
- Authority
- MX
- Mexico
- Prior art keywords
- glycopyranosidase
- acetamido
- deoxy
- glycoprotein
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642932P | 2018-03-14 | 2018-03-14 | |
| US201862690536P | 2018-06-27 | 2018-06-27 | |
| US201862699443P | 2018-07-17 | 2018-07-17 | |
| PCT/US2019/021995 WO2019178191A1 (en) | 2018-03-14 | 2019-03-13 | O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009530A true MX2020009530A (es) | 2021-01-15 |
Family
ID=65952097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009530A MX2020009530A (es) | 2018-03-14 | 2019-03-13 | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230117898A1 (enExample) |
| EP (2) | EP3765458B1 (enExample) |
| JP (1) | JP7453916B2 (enExample) |
| CN (2) | CN112218863B (enExample) |
| AU (1) | AU2019234759C1 (enExample) |
| CA (1) | CA3093315A1 (enExample) |
| ES (1) | ES2942211T3 (enExample) |
| MA (1) | MA52004A (enExample) |
| MX (1) | MX2020009530A (enExample) |
| WO (1) | WO2019178191A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018154133A1 (en) * | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
| US12180205B2 (en) * | 2018-09-19 | 2024-12-31 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
| WO2021094312A1 (en) | 2019-11-11 | 2021-05-20 | Janssen Pharmaceutica Nv | Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds |
| WO2021110656A1 (en) | 2019-12-02 | 2021-06-10 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| US20230058733A1 (en) | 2019-12-18 | 2023-02-23 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| CN114867725A (zh) | 2019-12-18 | 2022-08-05 | 詹森药业有限公司 | Oga抑制剂化合物 |
| WO2021123291A1 (en) | 2019-12-18 | 2021-06-24 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| KR102533471B1 (ko) * | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 |
| CN114213315A (zh) * | 2021-12-31 | 2022-03-22 | 上海陶术生物科技有限公司 | 含氮杂环类化合物及其中间体的合成方法 |
| CN114560805B (zh) * | 2022-01-20 | 2024-11-29 | 上海陶术生物科技有限公司 | 含氮杂环化合物及其中间体的合成方法 |
| WO2026021588A1 (zh) * | 2024-07-26 | 2026-01-29 | 浙江同源康医药股份有限公司 | Oga抑制剂及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP2780014A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5989805B2 (ja) | 2012-02-10 | 2016-09-07 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | メチル基変更酵素の調節物質、組成物及びその使用 |
| MA38341B1 (fr) | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| PT2970272T (pt) * | 2013-03-14 | 2019-06-05 | Merck Patent Gmbh | Inibidores de glicosidase |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3389658B1 (en) * | 2015-12-18 | 2020-11-25 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
| EP3555087A1 (en) * | 2016-12-16 | 2019-10-23 | Janssen Pharmaceutica NV | Monocyclic oga inhibitor compounds |
| US20190359609A1 (en) | 2016-12-16 | 2019-11-28 | Janssen Pharmaceutica Nv | Bicyclic oga inhibitor compounds |
| WO2018154133A1 (en) * | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
-
2019
- 2019-03-13 JP JP2020548963A patent/JP7453916B2/ja active Active
- 2019-03-13 MX MX2020009530A patent/MX2020009530A/es unknown
- 2019-03-13 WO PCT/US2019/021995 patent/WO2019178191A1/en not_active Ceased
- 2019-03-13 EP EP19713945.4A patent/EP3765458B1/en active Active
- 2019-03-13 CA CA3093315A patent/CA3093315A1/en active Pending
- 2019-03-13 ES ES19713945T patent/ES2942211T3/es active Active
- 2019-03-13 CN CN201980019170.5A patent/CN112218863B/zh active Active
- 2019-03-13 AU AU2019234759A patent/AU2019234759C1/en active Active
- 2019-03-13 CN CN202410813893.5A patent/CN118955490A/zh active Pending
- 2019-03-13 EP EP23151036.3A patent/EP4186899A1/en active Pending
- 2019-03-13 MA MA052004A patent/MA52004A/fr unknown
-
2022
- 2022-08-24 US US17/894,461 patent/US20230117898A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019234759C1 (en) | 2025-02-06 |
| JP2021518340A (ja) | 2021-08-02 |
| CN112218863A (zh) | 2021-01-12 |
| US20230117898A1 (en) | 2023-04-20 |
| EP4186899A1 (en) | 2023-05-31 |
| ES2942211T3 (es) | 2023-05-30 |
| AU2019234759B2 (en) | 2024-08-01 |
| CA3093315A1 (en) | 2019-09-19 |
| AU2019234759A1 (en) | 2020-09-17 |
| JP7453916B2 (ja) | 2024-03-21 |
| WO2019178191A1 (en) | 2019-09-19 |
| CN112218863B (zh) | 2024-07-12 |
| EP3765458A1 (en) | 2021-01-20 |
| CN118955490A (zh) | 2024-11-15 |
| MA52004A (fr) | 2021-01-20 |
| WO2019178191A8 (en) | 2019-12-26 |
| EP3765458B1 (en) | 2023-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
| CL2023003041A1 (es) | Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| CL2019003086A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
| UY37710A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| MX2023011675A (es) | Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia. | |
| UY35362A (es) | Compuestos terapéuticos | |
| MX2020010508A (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados. | |
| AR107864A1 (es) | ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS | |
| MX2021004593A (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. | |
| MX2019004578A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MX392213B (es) | Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano. | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| DOP2022000068A (es) | COMPUESTOS HETEROCÍCLICOS DE ARILMETILENO COMO BLOQUEADORES DEL CANAL SHAKER DE POTASIO Kv1.3 | |
| CO2021004873A2 (es) | Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
| MX2024009926A (es) | Composiciones y metodos para tratar trastornos del snc. | |
| CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| UY36124A (es) | Derivados de carboxamida | |
| CL2024001044A1 (es) | Formas de sal de un receptor del componente c5a del complemento | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| UY36123A (es) | Derivados de carboxamida | |
| MX2021004917A (es) | Sales cristalinas de un inhibidor de calicreina plasmatica. |